AlTi Global Inc. Purchases New Shares in Celcuity, Inc. $CELC

AlTi Global Inc. acquired a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,287 shares of the company’s stock, valued at approximately $261,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. ProShare Advisors LLC bought a new stake in Celcuity in the third quarter worth $249,000. Candriam S.C.A. boosted its stake in Celcuity by 48.3% in the 3rd quarter. Candriam S.C.A. now owns 390,924 shares of the company’s stock worth $19,312,000 after purchasing an additional 127,348 shares in the last quarter. Murphy Pohlad Asset Management LLC purchased a new stake in Celcuity during the 3rd quarter valued at about $445,000. Allianz Asset Management GmbH bought a new stake in Celcuity during the 3rd quarter valued at about $400,000. Finally, Ogorek Anthony Joseph NY ADV bought a new stake in Celcuity during the 3rd quarter valued at about $27,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Jefferies Financial Group lifted their target price on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Stifel Nicolaus lifted their price objective on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Craig Hallum boosted their target price on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Sunday, October 26th. Finally, Wolfe Research initiated coverage on shares of Celcuity in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.25.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the transaction, the director owned 90,000 shares of the company’s stock, valued at $10,802,700. The trade was a 18.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard E. Buller sold 3,900 shares of the company’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the sale, the director owned 7,260 shares of the company’s stock, valued at approximately $702,259.80. This represents a 34.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 26,900 shares of company stock worth $3,094,917 in the last three months. 15.77% of the stock is owned by insiders.

Celcuity Stock Performance

Shares of Celcuity stock opened at $104.23 on Thursday. The firm has a fifty day moving average of $105.43 and a two-hundred day moving average of $77.36. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The stock has a market capitalization of $4.82 billion, a price-to-earnings ratio of -28.40 and a beta of 0.36. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. As a group, equities research analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.